InsiderTrades.com logo
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research   |   Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.

KPRX Insider Trading

Insider Ownership Percentage: 1.50%
Insider Buying (Last 12 Months): $64,388.79
Insider Selling (Last 12 Months): $0.00

Kiora Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Kiora Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Kiora Pharmaceuticals Share Price & Price History

Current Price: $3.45
Price Change: ▲ Price Increase of +0.01 (0.29%)
As of 12/3/2024 06:16 PM ET

This chart shows the closing price history over time for KPRX up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
Coins Set to Soar with a Pro-Crypto White House
From Crypto 101 Media   |   Ad
Coins Set to Soar with a Pro-Crypto White House President-Elect Donald Trump is reported to be holding over $3 Million worth of crypto – and he's not the only one at the top interested in digital assets…
Click here to reserve your free seat at the Crypto Community Summit

Kiora Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
9/10/2024Aron ShapiroDirectorBuy3,000$3.60$10,800.003,000View SEC Filing Icon  
8/19/2024Lisa Walters-HoffertDirectorBuy1,250$3.86$4,825.001,250View SEC Filing Icon  
6/14/2024Eric Joseph DanielsInsiderBuy1,431$5.29$7,569.9911,222View SEC Filing Icon  
6/14/2024Melissa ToscaEVPBuy100$5.25$525.003,979View SEC Filing Icon  
6/13/2024Brian M StremCEOBuy3,000$5.00$15,000.0014,531View SEC Filing Icon  
6/13/2024Erin ParsonsDirectorBuy5,260$4.88$25,668.805,260View SEC Filing Icon  
See Full Table
“Fed Proof” Your Bank Account with THESE 4 Simple Steps
From Weiss Ratings   |   Ad
Starting as soon as a few months from now, the United States government will make a sweeping change to bank accounts nationwide. It will give them unprecedented powers to control your bank account.
Learn these 4 simple steps and protect your savings before it’s too late.

SEC Filings (Institutional Ownership Changes) for Kiora Pharmaceuticals (NASDAQ:KPRX)

76.97% of Kiora Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at KPRX by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Kiora Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/21/2024Stonepine Capital Management LLC200,000$0.84M0.8%N/A6.856%Search for SEC Filing on Google Icon
8/20/2024Nantahala Capital Management LLC211,110$0.89M0.1%-88.9%7.237%Search for SEC Filing on Google Icon
8/7/2024AIGH Capital Management LLC255,561$1.07M0.3%-88.9%8.761%Search for SEC Filing on Google Icon
7/12/2024Rosalind Advisors Inc.255,555$1.07M0.8%-88.9%8.752%Search for SEC Filing on Google Icon
4/25/2024Rosalind Advisors Inc.2,300,000$1.62M1.5%N/A8.759%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Kiora Pharmaceuticals logo
Kiora Pharmaceuticals, Inc., a clinical-stage specialty pharmaceutical company, develops and commercializes therapies for the treatment of ophthalmic diseases in the United States. Its lead product is KIO-301, a potential vision-restoring small molecule, which is in Phase 1b clinical trial that acts as a photoswitch to restore vision in patients with inherited and age-related degenerative retinal diseases. The company is also developing KIO-101, an eye drop that is in Phase 2 clinical trial for the treatment of ocular presentation of rheumatoid arthritis, and KIO-104 for the treatment of posterior non-infectious uveitis; and KIO-201, an eye drop, which is in Phase 3b clinical trial for treating patients undergoing photorefractive keratectomy (PRK) surgery for corneal wound repair. The company was formerly known as Eyegate Pharmaceuticals, Inc. and changed its name to Kiora Pharmaceuticals, Inc. in November 2021. Kiora Pharmaceuticals, Inc. was incorporated in 1998 and is headquartered in Encinitas, California.
Read More on Kiora Pharmaceuticals

Today's Range

Now: $3.45
Low: $3.35
High: $3.53

50 Day Range

MA: $3.48
Low: $3.10
High: $4.04

52 Week Range

Now: $3.45
Low: $3.00
High: $8.98

Volume

7,024 shs

Average Volume

71,140 shs

Market Capitalization

$10.35 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Who are the company insiders with the largest holdings of Kiora Pharmaceuticals?

Kiora Pharmaceuticals' top insider investors include:
  1. Brian M Strem (CEO)
  2. Eric Joseph Daniels (Insider)
  3. Erin Parsons (Director)
  4. Melissa Tosca (EVP)
  5. Aron Shapiro (Director)
  6. Lisa Walters-Hoffert (Director)
Learn More about top insider investors at Kiora Pharmaceuticals.
Missed Nvidia? Buy Elon Musk’s “Silent Partner”
From Brownstone Research   |   Ad
In February 2016, when almost nobody was talking about artificial intelligence… I picked Nvidia as one of my favorite stocks. Today, it’s probably the most popular stock in the world. I believe this Elon Musk “silent partner” could be the next big AI winner.
So please click here to see the details because a lot of people could get rich.